Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics
Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics
复制标题
DOI：
10.1111/bjh.13484
复制
发表时间：
2015-08-01
影响因子：
6.5
通讯作者：
Galieni, Piero
中科院分区：
文献类型：
--
作者：
Vagnoni, Davide;Travaglini, Fosco;Galieni, Piero
多发性骨髓瘤 (MM) 患者循环浆细胞 (PC) 的检测是众所周知的预后因素。我们通过流式细胞术 (FC) 对 104 名诊断时患有活动性 MM 的患者进行了 CD38(+)CD45(-) 细胞门控评估循环 PC，并检查了它们与细胞遗传学风险的关系。患者平均随访 36 个月。通过使用接受者操作特征分析，我们估计用于定义不良预后的循环 PC 的最佳截止值为 41。具有高风险细胞遗传学的患者 (n = 24) 预后不良，与循环 PC 水平无关 [PC
Detection of circulating plasma cells (PCs) in multiple myeloma (MM) patients is a well-known prognostic factor. We evaluated circulating PCs by flow cytometry (FC) in 104 patients with active MM at diagnosis by gating on CD38(+)CD45(-)cells and examined their relationship with cytogenetic risk. Patients had an average follow-up of 36months. By using a receiver operating characteristics analysis, we estimated the optimal cut-off of circulating PCs for defining poor prognosis to be 41. Patients with high-risk cytogenetics (n=24) had poor prognosis, independently of circulating PC levels [PC